Avacta Group Plc (OTCMKTS:AVCTF – Get Free Report)’s stock price traded down 5.3% during trading on Friday . The stock traded as low as $0.8151 and last traded at $0.8151. 4,000 shares traded hands during mid-day trading, a decline of 37% from the average session volume of 6,379 shares. The stock had previously closed at $0.8611.
Avacta Group Stock Down 5.3%
The company has a 50-day moving average price of $1.03 and a two-hundred day moving average price of $0.78.
Avacta Group Company Profile
Avacta Group plc is a UK-based biotechnology company specializing in the discovery, development and commercialization of Affimer® biotherapeutics and diagnostic reagents. The company’s proprietary Affimer platform uses small, engineered protein scaffolds that can be tailored to bind specifically to target molecules, offering an alternative to traditional antibodies. Avacta operates two core divisions: Avacta Therapeutics, which focuses on novel treatments in oncology and immune-related diseases, and Avacta Analytical, which develops reagents and point-of-care diagnostic tests.
In its diagnostics business, Avacta has applied the Affimer technology to lateral flow assays, most notably for rapid detection of viral pathogens such as SARS-CoV-2.
Read More
- Five stocks we like better than Avacta Group
- Do not delete, read immediately
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- Can Any Expenses Be Deducted From Capital Gains Tax?
- Do you know what Amazon is planning for January 1?
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.
